Short and long terms clinical outcomes of Paclitaxel drug-eluting balloons applied for de-novo coronary artery lesions in the context of acute coronary syndrome: A real world experience.

A single-centre retrospective observational study aimed at observing the outcomes of using DEB in ACS patients. All-comer ninety patients were included with a follow-up of 12-36 months. DEBs were deployed successfully yielding TIMI 3 without significant coronary dissection. MACE was 1.1% and 3.3% for 30 days and 12-36 months respectively.